Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Huge Market Belies The Long And Difficult Road To Novel Pain Therapies

Executive Summary

Since the introduction of the first triptan for aborting migraine in 1992, no truly new class of pain drug – other than off-label use of existing anticonvulsants and antidepressants for neuropathic pain – has reached the market. In fact, the vast majority of pain sufferers today are treated little differently than they would have been a century ago.

Related Content

Topics

UsernamePublicRestriction

Register

PS053438

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel